In recent times, the landscape of tumor immunotherapy has been profoundly reshaped by the advent of immune checkpoint blockade therapy targeting the PD-1/PD-L1 axis, leading to a paradigm shift marked by remarkable therapeutic advancements across a diverse spectrum of malignancies. This evidence concerns the gene CD274 and neoplasm.